Introduction: For people with type 2 diabetes (T2DM) inadequately controlled with oral
INTRODUCTION
The worldwide burden of diabetes is increasing, with a projected prevalence of 366 million by 2030 [1] . A number of management strategies are currently in use for type 2 diabetes mellitus (T2DM), a progressive metabolic disorder characterized by a reduction in insulin production and secretion as well as increased where management with maximum-dose non-insulin monotherapy is inadequate after 3 months of treatment [3] .
Liraglutide is a once-daily GLP-1 RA that has been evaluated and shown to be effective and safe in randomized controlled trials (RCTs) and real-world studies throughout the T2DM treatment spectrum. Previous reviews have highlighted the improved glycemic control and favorable safety profile of the GLP-1 RA class of drugs [4] [5] [6] [7] [8] .
Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) are a novel class of once-daily OADs that target the kidneys, increasing urinary glucose excretion. As these treatments act independently of insulin, they have been found to be effective throughout the T2DM spectrum [9] [10] [11] . Evidence from several reviews of the clinical literature suggests that SGLT-2 inhibitors improve glycemic control while also offering a favorable weight profile and a low risk of hypoglycemia [9, [11] [12] [13] [14] .
Liraglutide and SGLT-2 inhibitors have not been compared against each other in head-to-head trials. Through a network meta-analysis (NMA) framework, which permits estimation of the relative treatment effects of interventions that have not been compared against each other in an RCT, we assessed the relative efficacy of liraglutide against SGLT-2 inhibitors among people with T2DM with inadequate glycemic control despite treatment with metformin alone or in combination with other OADs.
METHODS

Study Identification
A systematic literature review encompassing intervention search terms for liraglutide, canagliflozin, dapagliflozin, and empagliflozin for T2DM was conducted from inception to October 2014. For the purposes of the current analysis, the literature search was updated with terms specific to liraglutide and SGLT-2 inhibitors to identify recent relevant publications. In all iterations of the literature review, MEDLINE, target as well as the proportion of patients experiencing hypoglycemia.
In order to evaluate the consistency between direct and indirect comparisons, edge-splitting was performed [17] . This iterative technique involves splitting the available evidence into direct and indirect information for each comparison for which both are available. For each treatment comparison in the network, two relative treatment effects are estimated: one with pairwise comparison models based on direct comparisons and one based on an NMA of the remaining studies using indirect evidence only. After this assessment of inconsistency, the Bucher test was performed for each three-sided loop [18] . Both fixed-effects and random-effects models were fitted to the data using Bayesian Markov Chain Monte Carlo (MCMC) methods, and these models were compared using the deviance information criterion (DIC) to determine whether the randomor fixed-effects model was more appropriate [19] . 
Compliance with Ethics Guidelines
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RESULTS
Study Identification and Selection
A total of 21,554 abstracts were identified through the systematic literature search. From the 604 full-text publications included in the broader scope review, 28 publications describing 16 RCTs were selected for inclusion [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Throughout this process, the identification of eligible trials followed the PICOS design criteria outlined in Supporting Information 1. The database search for relevant studies is outlined in Supporting Information 2.
The flow of information diagram is presented in Fig. 1 .
The complete network of evidence is shown in Fig. 2 
Network Meta-Analyses
A random-effects NMA model was used to estimate outcomes for change in HbA1c, proportion of patients achieving HbA1c targets, mean change in FPG, and mean change in weight as the DIC suggested a better (52) 82 (19) 7.9 (0.8) The expected changes in HbA1c for each active intervention were modeled by combining the average placebo response with the relative treatment effect estimates of each treatment versus placebo (Fig. 3) . However, as each modeled response also includes uncertainty in the average placebo response, this figure should not be used to make statistical comparisons between treatments.
HbA1c Target
The odds ratios of achieving target HbA1c levels (\7% or B7%, depending on the target defined in the respective RCT) are presented in Table 3 .
All treatments, with the exception of dapagliflozin 5 mg, were found to be statistically more efficacious than placebo in achieving HbA1c targets. Liraglutide 1.8 mg Bars represent the estimated mean response and whiskers represent the 95% CrI. The estimate for placebo is a pooled response estimate based on the available data
Hypoglycemic Events
Both major and minor hypoglycemic events were considered separately in the NMA and no differences were observed between the treatments for which data were available. For major hypoglycemic events, data were available for liraglutide, canagliflozin, dapagliflozin, empagliflozin, and sitagliptin. The available data for minor hypoglycemic events was more limited, with outcomes only available for 
DISCUSSION
The purpose of this NMA was to compare the efficacy of liraglutide to SGLT-2 inhibitors among people with inadequately controlled T2DM despite treatment with metformin (alone or in combination with other OADs).
Across all outcomes evaluated in this analysis, liraglutide performed at least as well as SGLT-2 inhibitors. Management with liraglutide was found to present larger reductions in CFB in HbA1c or FPG, and reaching HbA1c targets (\7% or B7%). Differences between treatments based on these outcomes were particularly marked for comparisons to liraglutide 1.8 mg.
Moreover, liraglutide 1.8 mg was generally associated with more favorable outcomes. Few differences between liraglutide and SGLT-2 inhibitors in CFB in weight were observed.
This finding suggests that there are no weight-related consequences associated with the use of liraglutide over the use of other T2DM treatments included in our analysis. Overall, the analyses indicated better efficacy outcomes with liraglutide.
No differences were observed in terms of hypoglycemia. However, this outcome must be interpreted with caution, given the low numbers of hypoglycemic events observed in the included trials and, in the case of minor hypoglycemia, the limited number of interventions that were available for inclusion in the network.
The population included people previously treated with metformin monotherapy as well as those on metformin in combination with other OADs, including SUs, TZDs, and DPP-4s. The nature of the evidence base did not allow for separate NMAs for these subpopulations. As it is possible that the number of prior OADs is an 
